3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaHemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis diseaseRecruitingPhase 32026-10-08NCT07623200
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic TherapyBronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorderActive, not recruitingPhase 32026-08-25NCT06821542
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmActive, not recruitingPhase 22026-06-25NCT04509700